Srivatsava Naidu

Dr. Srivatsava Naidu


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2024 in Molecular Therapy Nucleic Acids
Verified
Journal Article
Open access
IKIndira Kundu
Indira Kundu
SVShivani Varshney
Shivani Varshney
SKSrikanth Karnati
Srikanth Karnati
SNSrivatsava Naidu
Srivatsava Naidu
Circular RNAs (circRNAs) represent a distinct class of covalently closed RNA species lacking conventional 5' to 3' polarity. Derived predominantly from pre-mRNA transcripts of protein-coding genes, circRNAs arise through back-splicing events of exon-exon or exon-intron junctions. They exhibit tissue- and cell-specific expression patterns and play crucial roles in regulating fundamental cellular processes such as cell cycle dynamics, proliferation, apoptosis, and differentiation. CircRNAs modulate gene expression through a plethora of mechanisms at epigenetic, transcriptional, and post-transcriptional levels, and some can even undergo translation into functional proteins. Recently, aberrant expression of circRNAs has emerged as a significant molecular aberration within the intricate regulatory networks governing hallmarks of cancer. The tumor-specific expression patterns and remarkable stability of circRNAs have profound implications for cancer diagnosis, prognosis, and therapy. This review comprehensively explores the multifaceted roles of circRNAs across cancer hallmarks in various tumor types, underscoring their growing significance in cancer diagnosis and therapeutic interventions. It also details strategies for leveraging circRNA-based therapies and discusses the challenges in using circRNAs for cancer management, emphasizing the need for further research to overcome these obstacles.

6 June 2023 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
SCSourav Chattopadhyay
Sourav Chattopadhyay
SSShashanka Shekhar Sarkar
Shashanka Shekhar Sarkar
SSSheetanshu Saproo
Sheetanshu Saproo
SYSheetal Yadav
Sheetal Yadav
DADeepika Antil
Deepika Antil
SNSrivatsava Naidu
Srivatsava Naidu
Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related deaths worldwide, with resistance to apoptosis being a major driver of therapeutic resistance and aggressive phenotype. This study aimed to develop a novel gene therapy approach for NSCLC by targeting resistance to apoptosis. Loss of function mutations of caspase 8 (CASP8) and downregulation of microRNAs (miRs) 29A-B1 and 34A were identified as key contributors to resistance to apoptosis in NSCLC. A biodegradable polymeric nano-gene delivery system composed of chitosan-poly-lactic-co-glycolic acid was formulated to deliver initiator CASP8 and miRs 29A-B1 and 34A. The nano-formulation efficiently encapsulated the therapeutic genes effectively internalized into NSCLC cells and induced significant apoptosis. Evaluation of the nano-formulation in A549 tumor spheroids showed a significant increase in apoptosis within the core of the spheroids, suggesting effective penetration into the spheroid structures. We provide a novel nano-formulation that demonstrate therapeutic potential for suicidal gene therapy in NSCLC.

17 October 2022 in Cancer Gene Therapy
Verified
Journal Article
Closed access
PDF file
SSSheetanshu Saproo
Sheetanshu Saproo
SSShashanka S. Sarkar
Shashanka S. Sarkar
EGEkta Gupta
Ekta Gupta
SCSourav Chattopadhyay
Sourav Chattopadhyay
ACAarzoo Charaya
Aarzoo Charaya
SNSrivatsava Naidu
Srivatsava Naidu

20 October 2025 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
SSShashanka Shekhar Sarkar
Shashanka Shekhar Sarkar
MSMansi Sharma
Mansi Sharma
AKArpita Karmakar
Arpita Karmakar
KJKousar Jahan
Kousar Jahan
SSSheetanshu Saproo
Sheetanshu Saproo
SNSrivatsava Naidu
Srivatsava Naidu
Aberrant upregulation of RNA polymerase I (Pol I) transcription and its dedicated machinery plays a pivotal role in tumor progression and chemoresistance. RRN3, a Pol I-specific transcription initiation factor, is frequently overexpressed in malignancies contributing to oncogenic processes. Despite the therapeutic potential of Pol I transcription inhibition, existing inhibitors lack specificity and are associated with DNA damage, mutagenicity, and toxicity, limiting their clinical utility. To fully realize the potential of Pol I-targeted cancer therapies, selective Pol I transcription inhibitors with minimal off-target effects are essential. Molecular docking and virtual screening were conducted to identify ligands targeting RRN3. Biochemical and spectroscopic analyses validated the direct ligand-RRN3 binding. The mechanism of action of the ligand was investigated through biochemical, cellular and molecular assays. Functional studies assessed the effects of the ligand on cancer cell viability, clonogenicity, cell cycle progression, and apoptosis, in comparison to non-cancerous cells. The ligand efficacy was further evaluated in chemoresistant cancer cell lines and 3D tumor spheroid models. Genotoxicity and mutagenicity were assessed using DNA damage and mutagenicity assays. We demonstrate that (N-(1-amidino-2-thiourea-alkyl-7-chloroquinoline-4-amine)) (NSH76) selectively inhibits Pol I transcription by disrupting the Pol I pre-initiation complex at the rDNA promoter through direct RRN3 binding. Notably, NSH76 does not affect cMyc expression, a Pol II-driven transcript, confirming its specificity. NSH76 preferentially inhibits Pol I transcription in cancer cells with high RRN3 expression, while sparing non-cancerous cells with low RRN3 levels. Functionally, NSH76 exhibits potent antiproliferative activity against cancer cells, with minimal impact on non-cancerous cells. NSH76 induces cell cycle arrest, suppresses clonogenicity, and significantly enhances apoptosis in cancer cells, including cisplatin- and doxorubicin-resistant cell lines. These effects are recapitulated in 3D tumor spheroid assays. Furthermore, NSH76 triggers nucleolar stress, leading to the activation of tumor suppressors p53 and p21. Notably, NSH76 does not induce DNA damage or mutagenicity. These findings establish NSH76 as a potent and selective Pol I inhibitor with significant therapeutic potential in cancer and possible implications for overcoming chemoresistance.

5 October 2024 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
SSShashanka Shekhar Sarkar
Shashanka Shekhar Sarkar
MSMansi Sharma
Mansi Sharma
SSSheetanshu Saproo
Sheetanshu Saproo
SNSrivatsava Naidu
Srivatsava Naidu
Hyperactive RNA Polymerase I (Pol I) transcription is canonical in cancer, associated with malignant proliferation, poor prognosis, epithelial-mesenchymal transition, and chemotherapy resistance. Despite its significance, the molecular mechanisms underlying Pol I hyperactivity remain unclear. This study aims to elucidate the role of long noncoding RNAs (lncRNAs) in regulating Pol I transcription in lung adenocarcinoma (LUAD). Bioinformatics analyses were applied to identify lncRNAs interacting with Pol I transcriptional machinery. Fluorescence in situ hybridization was employed to examine the nucleolar localization of candidate lncRNA in LUAD cells. RNA immunoprecipitation assay validated the interaction between candidate lncRNA and Pol I components. Chromatin isolation by RNA purification and Chromatin Immunoprecipitation (ChIP) were utilized to confirm the interactions of candidate lncRNA with Pol I transcriptional machinery and the rDNA core promoter. Functional analyses, including lncRNA knock-in and knockdown, inhibition of Pol I transcription, quantitative PCR, cell proliferation, clonogenicity, apoptosis, cell cycle, wound-healing, and invasion assays, were performed to determine the effect of candidate lncRNA on Pol I transcription and associated malignant phenotypes in LUAD cells. ChIP assays and luminometry were used to investigate the transcriptional regulation of the candidate lncRNA. We demonstrate that oncogenic LINC01116 scaffolds essential Pol I transcription factors TAF1A and TAF1D, to the ribosomal DNA promoter, and upregulate Pol I transcription. Crucially, LINC01116-driven Pol I transcription activation is essential for its oncogenic activities. Inhibition of Pol I transcription abrogated LINC01116-induced oncogenic phenotypes, including increased proliferation, cell cycle progression, clonogenicity, reduced apoptosis, increased migration and invasion, and drug sensitivity. Conversely, LINC01116 knockdown reversed these effects. Additionally, we show that LINC01116 upregulation in LUAD is driven by the oncogene c-Myc, a known Pol I transcription activator, indicating a functional regulatory feedback loop within the c-Myc-LINC01116-Pol I transcription axis. Collectively, our findings reveal, for the first time, that LINC01116 enhances Pol I transcription by scaffolding essential transcription factors to the ribosomal DNA promoter, thereby driving oncogenic activities in LUAD. We propose the c-Myc-LINC01116-Pol I axis as a critical oncogenic pathway and a potential therapeutic target for modulating Pol I transcription in LUAD.

10 January 2023 in Frontiers in Molecular Biosciences
Verified
Journal Article
Open access
SSSheetanshu Saproo
Sheetanshu Saproo
SSShashanka S. Sarkar
Shashanka S. Sarkar
VGVishakha Gautam
Vishakha Gautam
CKChingmei W. Konyak
Chingmei W. Konyak
GDGouri Dass
Gouri Dass
SNSrivatsava Naidu
Srivatsava Naidu
Oral squamous cell carcinoma (OSCC) is the second leading cause of cancer-related morbidity and mortality in India. Tobacco, alcohol, poor oral hygiene, and socio-economic factors remain causative for this high prevalence. Identification of non-invasive diagnostic markers tailored for Indian population can facilitate mass screening to reduce overall disease burden. Saliva offers non-invasive sampling and hosts a plethora of markers for OSCC diagnosis. Here, to capture the OSCC-specific salivary RNA markers suitable for Indian population, we performed RNA-sequencing of saliva from OSCC patients (n = 9) and normal controls (n = 5). Differential gene expression analysis detected an array of salivary RNAs including mRNAs, long non-coding RNAs, transfer-RNAs, and microRNAs specific to OSCC. Computational analysis and functional predictions identified protein kinase c alpha (PRKCA), miR-6087, miR-449b-5p, miR-3656, miR-326, miR-146b-5p, and miR-497-5p as potential salivary indicators of OSCC. Notably, higher expression of PRKCA, miR-6087 and miR-449b-5p were found to be associated with therapeutic resistance and poor survival, indicating their prognostic potential. In addition, sequencing reads that did not map to the human genome, showed alignments with microbial reference genomes. Metagenomic and statistical analysis of these microbial reads revealed a remarkable microbial dysbiosis between OSCC patients and normal controls. Moreover, the differentially abundant microbial taxa showed a significant association with tumor promoting pathways including inflammation and oxidative stress. Summarily, we provide an integrated landscape of OSCC-specific salivary RNAs relevant to Indian population which can be instrumental in devising non-invasive diagnostics for OSCC.